An observational study in Charcot-Marie-Tooth Disease, Type Ia (Disorder) and HMSN, sponsored by University of Iowa. Recruiting at 24 sites in 6 countries. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by University of Iowa · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Charcot-Marie-Tooth Disease with a site in United States — 9 open to participants now, 14 under way, 2 of them phase 3. Charcot-Marie-Tooth Disease · United States.
Among the 41 studies in Charcot-Marie-Tooth Disease with a site in United States, this one is the 6th largest by planned enrollment of the 21 observational ones that give a count, is one of 3 that started in 2010, is one of 21 observational ones, reaches primary completion later than 7 of the 13 other live ones, and was the 3rd registered.
115 studies on the registry are indexed under Charcot-Marie-Tooth Disease; 39 are open to participants now.
Browse Charcot-Marie-Tooth Disease studies →9 of the 41 studies in Charcot-Marie-Tooth Disease with a site in United States are open now. Recruiting first, the newest first:
Bopha Chrea · Sites in United States
Ages 25–55
University of California, San Francisco · Sites in United States
National Human Genome Research Institute (NHGRI) · Sites in United States
Ages 1 mo–100 yrs
New York Stem Cell Foundation Research Institute · Sites in United States
Ages 5+ · Healthy volunteers
Children's Hospital of Philadelphia · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 31 Charcot-Marie-Tooth Disease studies recruiting now, 14 (45%) set no upper age limit and 13 (42%) stop at 75 or younger; 14 take children under 18; 13 take healthy volunteers.
This study: all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 9 · Phase 3 5
First in 2007; this study’s year is marked. 3 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,050 is above the median of 120 across 49 observational studies indexed under Charcot-Marie-Tooth Disease.
Median enrollment 30 across the 20 interventional studies, 291 across the 21 observational. Of the 24 that completed or were terminated, 5 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 41 have an industry lead sponsor. The 10 most frequent:
University of Iowa is the lead sponsor of 279 studies on the registry; 32 are open to participants now.
Of its 45 completed or terminated interventional studies of FDA-regulated products, 40 (89%) have results posted.
University of Iowa has 4 studies filed under Charcot-Marie-Tooth Disease — fewer than ten, so there is no comparison to draw.
1 of the studies in Charcot-Marie-Tooth Disease with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07223632Vanda PharmaceuticalsTreatment of Charcot-Marie-Tooth Disease, Axonal, Type 2S (CMT2S) in an Individual Patient | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 41 studies in Charcot-Marie-Tooth Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This project includes two projects. One is looking for new genes that cause Charcot Marie Tooth disease (CMT). The other is looking for genes that do not cause CMT, but may modify the symptoms a person has.
This project is to understand modifier genes and how they influence the severity of disease expression, along with identifying new forms of CMT which have not been genetically determined. Subjects who are eligible will either have CMT type 1A (CMT1A) or an unknown form of CMT. Blood will be drawn and sent to the University of Miami where they receive the coded sample and process it through exome sequencing. Subjects will be told that this is optional.
The criteria were revised on the registry on Oct 16, 2026. See what changed
Patients participating in Inherited Neuropathies Consortium (INC)-6601 and meeting eligibility criteria for this study will be recruited.
Inclusion Criteria:
Patients:
o Must have demonstrated neuropathy on nerve conduction studies or a clinically diagnosed hereditary neuropathy, in the opinion of the site investigator.
Controls:
CMT1A Modifier Study
Inclusion Criteria:
AND/OR
Exclusion Criteria
Families/people with genetically defined CMT1A
Families/people with genetically undefined CMT with common causes ruled out.
Charcot Marie Tooth disease type 1A (CMT1A) gene modifiers
While the same genetic change - an extra copy of PMP22 - causes CMT1A by definition, it is unclear why some people have more severe symptoms and some have less severe. We are looking for genetic modifiers - changes in the DNA that may be causing the differences in symptoms.
Time frame: once
New genetic causes of CMT
At least 33% of people with CMT have an unknown or genetically un-found form of the condition. We are looking for additional genes that cause CMT when mutated.
Time frame: Once
Plan to share: Yes — De-identified RDCRN data is submitted to an ORDR-designated repository. For the current grant cycle, that repository has been dbGaP
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: (For Observational/Longitudinal/Natural History/Epidemiology studies): For the current grant cycle, available data will be released to the repository and will become available to the scientific community one year after publication of planned analyses, or after a period of 5 years from the date when the data were collected, whichever comes first.
Access criteria: - For the current grant cycle, once de-identified data is posted on dbGaP, a summary of the study is posted and individual participant data is accessed via a request through dbGaP.
Data sharing details ↗ · www.ncbi.nlm.nih.gov
Started May 2010 (actual). Primary completion is estimated for Dec 2030, 247 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Dec 2026 → Dec 2030 and completion Dec 2026 → Dec 2030.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.